Estrogenic Endocrine Disrupting Compounds Increase Cell Proliferation and Cancer Stemness in Estrogen Receptor Positive Breast Cancer Cells
RNA-seq (gene expression) · human · 24 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Breast cancerThis series is part of our curated briefing on it.
- Samples
- 24 samples: 8 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- The Endocrine Disrupting Compounds Bisphenol-A and α-Zeranol Mimic the Estrogen Transcriptional Program to Promote Proliferation and Stemness in Breast Cancer CellsMolecular carcinogenesis · 2026
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE311462_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1369499 and SRA study SRP648940. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 24 samples.
How we read this: 8 replicated groups read from 24 sample titles; they account for 24 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9325561 MCF7 control 12 hours rep 1 MCF7 control 12 hours
- GSM9325562 MCF7 control 72 hours rep 1 MCF7 control 72 hours
- GSM9325563 MCF7 control 12 hours rep 2 MCF7 control 12 hours
- GSM9325564 MCF7 control 72 hours rep 2 MCF7 control 72 hours
- GSM9325565 MCF7 control 12 hours rep 3 MCF7 control 12 hours
- GSM9325566 MCF7 control 72 hours rep 3 MCF7 control 72 hours
- GSM9325567 MCF7 E2 12 hours rep 1 MCF7 E2 12 hours
- GSM9325568 MCF7 E2 72 hours rep 1 MCF7 E2 72 hours
- GSM9325569 MCF7 E2 12 hours rep 2 MCF7 E2 12 hours
- GSM9325570 MCF7 E2 72 hours rep 2 MCF7 E2 72 hours
- GSM9325571 MCF7 E2 12 hours rep 3 MCF7 E2 12 hours
- GSM9325572 MCF7 E2 72 hours rep 3 MCF7 E2 72 hours
- GSM9325573 MCF7 BPA 12 hours rep 1 MCF7 BPA 12 hours
- GSM9325574 MCF7 BPA 72 hours rep 1 MCF7 BPA 72 hours
- GSM9325575 MCF7 BPA 12 hours rep 2 MCF7 BPA 12 hours
- GSM9325576 MCF7 BPA 72 hours rep 2 MCF7 BPA 72 hours
- GSM9325577 MCF7 BPA 12 hours rep 3 MCF7 BPA 12 hours
- GSM9325578 MCF7 BPA 72 hours rep 3 MCF7 BPA 72 hours
- GSM9325579 MCF7 aZAL 12 hours rep 1 MCF7 aZAL 12 hours
- GSM9325580 MCF7 aZAL 72 hours rep 1 MCF7 aZAL 72 hours
- GSM9325581 MCF7 aZAL 12 hours rep 2 MCF7 aZAL 12 hours
- GSM9325582 MCF7 aZAL 72 hours rep 2 MCF7 aZAL 72 hours
- GSM9325583 MCF7 aZAL 12 hours rep 3 MCF7 aZAL 12 hours
- GSM9325584 MCF7 aZAL 72 hours rep 3 MCF7 aZAL 72 hours
- GSE104675 Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 6 samples same disease briefing · shares endocrine
- GSE104193 Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signalling and malignant features in vitro and in vivo 32 samples same disease briefing
- GSE10885 An integromic analysis reveals that metaplastic carcinomas are distinct from basal-like tumors. 244 samples same disease briefing
- GSE10886 A Supervised Risk Predictor of Breast Cancer Based on Biological Subtypes 226 samples same disease briefing
- GSE11121 The humoral immune system has a key prognostic impact in node-negative breast cancer 200 samples same disease briefing
- GSE157605 RNA sequencing data of PC3, an androgen negative human prostate cell line, treated with estrogenic compounds 12 samples shares estrogenic, compounds, estrogen
- GSE299960 Increased LEF1 protein levels and isoform switching drive cell proliferation in chronic lymphocytic leukemia [CUT&Run] 70 samples shares proliferation, increase
- GSE280618 H3K27me3 chromatin heterogeneity reveals variable cell responses to estrogen and endocrine treatment 34 samples shares endocrine, estrogen
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.